<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754596</url>
  </required_header>
  <id_info>
    <org_study_id>GC-009</org_study_id>
    <nct_id>NCT02754596</nct_id>
  </id_info>
  <brief_title>Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution</brief_title>
  <official_title>Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant
      to timolol ophthalmic solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized trial comparing two elution doses of the Travoprost Intraocular implant
      to timolol ophthalmic solution in patients with open-angle glaucoma. Study assessments will
      include IOP and medication use as well as safety parameters.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) measured in mm Hg</measure>
    <time_frame>12 weeks</time_frame>
    <description>IOP reduction--mean diurnal values from 8am, 10 am, and 4 pm</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Post-op through 12 weeks</time_frame>
    <description>The number and percent of adverse events will be reported</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Glaucoma Open-angle</condition>
  <arm_group>
    <arm_group_label>Travoprost Intraocular Implant, high elution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This implant will be surgically implanted and elute travoprost, a prostaglandin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost Intraocular Implant, low elution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This implant will be surgically implanted and elute travoprost, a prostaglandin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Maleate Ophthalmic Solution, 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol, a beta blocker, will be dosed twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Intraocular Implant, high elution</intervention_name>
    <description>Surgical implant placed within the eye to elute travoprost.</description>
    <arm_group_label>Travoprost Intraocular Implant, high elution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Intraocular Implant, low elution</intervention_name>
    <description>Surgical implant placed within the eye to elute travoprost</description>
    <arm_group_label>Travoprost Intraocular Implant, low elution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate Ophthalmic Solution, 0.5%</intervention_name>
    <description>Instillation of one drop of timolol in the study eye twice daily</description>
    <arm_group_label>Timolol Maleate Ophthalmic Solution, 0.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open angle glaucoma

        Exclusion Criteria:

          -  Uveitic, neovascular, or angle closure glaucoma; or glaucoma associated with vascular
             disorders.

          -  Functionally significant visual field loss, including severe nerve fiber bundle
             defects.

          -  Prior glaucoma surgery.

          -  Uncontrolled systemic disease, pregnant females or those planning a pregnancy.

          -  Other ocular status conditions, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Wells, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Glaukos Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Berdahl, MD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

